BioCentury on BioBusiness,
How biotech fits into growth funds
Monday, May 10, 1993
How biotech fits into growth funds
By Karen Bernstein
Growth fund managers haven't dampened their long-term enthusiasm
for biotechnology stocks, retaining their belief that the sector ultimately will fit the
growth stock model of double-digit annual earnings growth. But in the near term, most are
only nibbling at stocks if they are buying at all, and they have little appetite for new
Biotech shares are competing for space in growth fund portfolios with
stocks that are making money: software companies such as Microsoft and Novell; hardware
companies such as Intel, Dell Computer and Motorola; consumer goods companies like
Coca-Cola and Gillette; retailers like Wal-Mart and Home Depot; insurance companies such
as American International Group; and pharmaceutical companies such as Merck, Glaxo and
Who's making money?
When biotech stocks are out of favor, the contrast between the
stage of development at which they typically go public compared to companies in other
sectors is intensified. "All the companies our high-tech analyst owns are making
money," said William Chester of Denver Investment Advisors. "They're making
money before they go public. I don't know that our high-tech analyst has ever bought a
high-tech company on its prospects."
Typical growth stocks have earnings growth of 20 percent to 25 percent
on a three-year horizon, according to Cam Philpott of Montgomery Asset Management, who
likes to buy stocks where the forward price/earnings multiple is one-half to two-thirds of
its growth rate.
Biotechs aren't taking up much room in many growth portfolios at the
moment. They make up about one-half percent of Chester's diversified medium-cap growth
fund. Chester started getting out of biotech in early 1992. His largest holding now is
CellPro, and he also has positions in Liposome Technology and North American Vaccine.
Pay less today
"I'm in a wait-and-see mode," said Chester, who got
burned on Synergen. "We don't have to own them because we run a diversified fund. We
still think of them as growth stocks, but the discount rate has gone up significantly.
We've increased our risk factor and we're willing to pay less today than two years ago. We
have less confidence in our ability to predict the outcome for any individual stock.
"Earnings are important, so we've got a renewed emphasis on Tier 1
companies, though I don't own any right now - because of disappointments that have
occurred and maybe some of these stocks are a little bit ahead of
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]